Hospital Acquired Pneumonia Drugs Market to Witness Robust Expansion by 2029

Hospital acquired pneumonia drugs market is anticipated to grow at a significant CAGR during the forecast period. The major factors that are expected to accelerate the growth of the market include increasing risk factors with longer hospital stays. Pneumonia is a leading cause of death across the globe with a fatality rate of 4-10%. Hospital-acquired pneumonia is the most common form among the others and it has a huge impact on the lifestyle of the patient. Further, it is associated with a high mortality rate and requires immediate medical intervention. Owing to this, there is a huge demand for pharmacological intervention for effective management of the disease. According to Infectious Control and Epidemiology, the overall incidence in the US is 1.6% and represents 3.63 per 1000 patients. Increasing prevalence among the healthcare settings led to the potential growth of the market.

Hospital-acquired pneumonia is acquired by patients after they are being admitted to the hospital for more than 48 hours. The public healthcare system is facing a tough challenge in the form of hospital-acquired pneumonia as it is the second most common hospital-acquired infection. Pneumonia causes agitation of the lungs and mainly affects the alveoli which are microscopic air sacs. Primary causes of hospital-acquired pneumonia are bacteria or viral infections and they can be differentiated based on how the infection was acquired by the patient. In order to maintain a strong position in the market, these market players are adopting various strategic moves, such as product launches, partnerships and collaborations, and mergers and acquisitions. For instance, in July 2019, Bayer Healthcare partnered with Cubist pharmaceutical Inc. and co-developed Sivextro, an antibiotic for hospital-acquired pneumonia treatment.

To Request a Sample of our Report on Hospital Acquired Pneumonia Drugs Market:  https://www.omrglobal.com/request-sample/hospital-acquired-pneumonia-drugs-market

Market Coverage

The market number available for - 2022-2030
Base year- 2022
Forecast period- 2023-2030
Segment Covered
Regions Covered- Globally
Competitive Landscape:Merck & Co., Inc., Pfizer Inc, and GlaxoSmithKline plc, among others.

Hospital Acquired Pneumonia Drugs Market Report by Segment

By Type

Antibacterial
Antiviral
Antifungal

By Application

Hospitals
Clinics
Others

A full Report of Hospital Acquired Pneumonia Drugs Market is Available at:  https://www.omrglobal.com/industry-reports/hospital-acquired-pneumonia-drugs-market

 Hospital Acquired Pneumonia Drugs Market by Region

North America

United States
Canada

Europe

UK
Germany
Spain
France
Italy
Rest of Europe

Asia-Pacific

India
China
Japan
South Korea
Rest of APAC

Rest of the World

Latin America
Middle East & Africa

Reasons to buy from us -

We cover more than 15 major industries, further segmented into more than 90 sectors.
More than 120 countries are for analysis.
Over 100+ paid data sources mined for investigation.
Our expert research analysts answer all your questions before and after purchasing your report.

Media Contact:

Company Name: Orion Market Research

Contact Person: Mr. Anurag Tiwari

Email: info@omrglobal.com

Contact no:  +91 7803040404

About Orion Market Research 

Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services. The company also offers Digital Marketing services through its subsidiary OMR Digital and Software development and Consulting Services through another subsidiary Encanto Technologies.

This release was published on openPR.